tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Dumont FJ et al. | A tacrolimus-related immunosuppressant with reduced toxicity. | 1998 | Transplantation | pmid:9448138 |
| Miyauchi T et al. | Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. | 1998 | Transplantation | pmid:9448139 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Levy G et al. | Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. | 2004 | Transplantation | pmid:15201658 |
| Roth D et al. | A prospective study of hepatitis C virus infection in renal allograft recipients. | 1996 | Transplantation | pmid:8623154 |
| O'Grady J | C(2) monitoring: out of the blocks but with some way to go! | 2004 | Transplantation | pmid:15201659 |
| Koprak S et al. | Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. | 1996 | Transplantation | pmid:8623162 |
| Adams PS et al. | Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome. | 2013 | Transplantation | pmid:23380870 |
| Josephson MA et al. | Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. | 2004 | Transplantation | pmid:15502727 |
| Yamagami S et al. | Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. | 1997 | Transplantation | pmid:9233699 |
| Takahara S et al. | The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. | 1992 | Transplantation | pmid:1373537 |
| Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
| David-Neto E et al. | The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. | 2007 | Transplantation | pmid:17627237 |
| Kasahara M et al. | Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. | 2001 | Transplantation | pmid:11211185 |
| Ovuworie CA et al. | Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. | 2001 | Transplantation | pmid:11685108 |
| Mourad G et al. | Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. | 2001 | Transplantation | pmid:11579299 |
| Roy A et al. | Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. | 2006 | Transplantation | pmid:16926593 |
| Welberry Smith MP et al. | Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. | 2013 | Transplantation | pmid:24056618 |
| Yang Z et al. | Long-term liver allograft survival induced by combined treatment with rAAV-hCTLA4Ig gene transfer and low-dose FK506. | 2003 | Transplantation | pmid:12589149 |
| Zhao WY et al. | Single kidneys transplanted from small pediatric donors less than 15 kilograms into pediatric recipients. | 2014 | Transplantation | pmid:25955345 |
| Benigni A et al. | The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | 1992 | Transplantation | pmid:1279848 |
| Nogueira JM et al. | A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. | 1999 | Transplantation | pmid:10096529 |
| Shapiro R et al. | Posttransplant diabetes in pediatric recipients on tacrolimus. | 1999 | Transplantation | pmid:10096540 |
| Prud'homme GJ et al. | GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. | 2013 | Transplantation | pmid:23851932 |
| Nashan B et al. | Clinical validation studies of Neoral C(2) monitoring: a review. | 2002 | Transplantation | pmid:12023607 |
| Bäckman L et al. | FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. | 1994 | Transplantation | pmid:7509516 |
| Woodle ES et al. | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. | 1996 | Transplantation | pmid:8830821 |
| Franz M et al. | Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? | 1998 | Transplantation | pmid:9825827 |
| Guerville F et al. | Transplantation with pathologic kidneys to improve the pool of donors: an example of shunt nephritis. | 2012 | Transplantation | pmid:22487813 |
| Mathis AS et al. | Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. | 2001 | Transplantation | pmid:11374405 |
| Mestres J et al. | Late subcapsular lymphocele in a kidney graft. | 2012 | Transplantation | pmid:22487814 |
| Mañez R et al. | Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. | 1995 | Transplantation | pmid:7537400 |
| Singla AK et al. | Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. | 2014 | Transplantation | pmid:24949498 |
| Chapman WC et al. | Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. | 2017 | Transplantation | pmid:28121741 |
| Ochiai T et al. | Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. | 1989 | Transplantation | pmid:2474208 |
| Sommerer C et al. | Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. | 2010 | Transplantation | pmid:20463649 |
| Walsh C et al. | Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients. | 2013 | Transplantation | pmid:23296149 |
| Froud T et al. | Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. | 2008 | Transplantation | pmid:19104407 |
| Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
| Oike F et al. | A 12-day course of FK506 allows long-term acceptance of semi-identical liver allograft in inbred miniature swine. | 2000 | Transplantation | pmid:10868630 |
| Gloor JM et al. | Subclinical rejection in tacrolimus-treated renal transplant recipients. | 2002 | Transplantation | pmid:12131699 |
| Johnson C et al. | Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. | 2000 | Transplantation | pmid:10755536 |
| Ekser B et al. | Hepatic function after genetically engineered pig liver transplantation in baboons. | 2010 | Transplantation | pmid:20606605 |
| Jain A et al. | Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. | 2005 | Transplantation | pmid:16210976 |
| Alloway R et al. | Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. | 2007 | Transplantation | pmid:17589351 |
| Yoo MC et al. | Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. | 2015 | Transplantation | pmid:25539464 |
| Uchikoshi F et al. | Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. | 1996 | Transplantation | pmid:8669109 |
| Dean PG et al. | Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. | 2004 | Transplantation | pmid:15239621 |
| Tian L et al. | Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft. | 2002 | Transplantation | pmid:12134113 |
| Gillard P et al. | Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. | 2008 | Transplantation | pmid:18212631 |